A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
Status:
Terminated
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate hemoglobin stability in subjects who had received
darbepoetin alfa for a minimum of 3 months prior to study entry who were then converted to
epoetin alfa at the same dosing frequency to maintain a hemoglobin level of 12 plus or minus
1 g/dL (range 11-13- g/dL).